Develop a business case for a new drug for the treatment of onchocerciasis and lymphatic filariasis
Client
Establishing the business case for investment in new drugs to treat the neglected tropical diseases onchocerciasis and lymphatic filariasis.
Goal
- To measure the health and economic outcomes of the roll-out of Moxidectin under different implementation scenarios as well as its production and financial requirements.
- To identify and model health outcomes of new treatments for onchocerciasis and lymphatic filariasis.
- To guide investment priorities for therapeutic approaches to the neglected tropical diseases of onchocerciasis and lymphatic filariasis.
Scope
MMGH convened stakeholders to define the use cases for Moxidectin, a new microfilaricide for the treatment of onchocerciasis and lymphatic filariasis. The use cases informed the modelling of the health impact of the drug under different implementation scenarios. This part of the the work was performed by the NTD Modelling Consortium. MMGH developed the estimate of the demand for the drug and, in collaboration with SDA Bocconi, assessed the drug cost-effectiveness. Finally, MMGH assembled all the information to provide a comprehensive view of the financial requirements and health impact of the drug.
Focus Area
Access